Funding for this research was provided by:
Text and Data Mining valid from 2019-12-01
Received: 25 April 2019
Accepted: 21 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: This study was approved by the MD Anderson Institutional Review Board.
: Not applicable.
: EM:• Advisory Committees – Genentech, Nektar Therapeutics• Honoraria – Astra Zeneca Pharmaceuticals, Merck & Co• Research Support – Pfizer, Astra Zeneca, Merck, BMS, GSK, and Tessa PharmaceuticalsVKL:• Advisory Committees – Takeda• Honoraria – Bristol Myers Squibb• Research Support – Guardant Health, Geneplus, Takeda, Adaptimmune.LAB:• Consulting – AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA.• Research Support – AbbVie, AstraZeneca, GenMab, Tolero Pharmaceuticals, Sierra OncologyPS:• Consulting – Constellation, Jounce, Kite Pharma, Neon, BioAtla, Pieris, Oncolytics, Merck, Forty-Seven, Polaris, Apricity, Marker Therapeutics, Codiak, ImaginAB.• Shareholder – Jounce, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB• Royalties and Licensing fees – JounceJA:• Consulting – Jounce, Kite Pharma, Neon, Amgen, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB, Tvardi Therapeutics, TapImmune.• Shareholder – Jounce, Neon, Constellation, Oncolytics, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, ImaginAB, TapImmune• Royalties and Licensing fees – Jounce, Merck, & BMSIIW:• Honoraria – Genentech/Roche, Bristol-Myers Squibb, Astra Zeneca/Medimmune, HTG Molecular, Merck, GlaxoSmithKline, and MSD.• Research Support – Genentech, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, and 4DJVH:• Advisory Committees – AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GSK, Guardant Health, Hengrui, Lilly, Novartis, Spectrum, EMD Serono, and Synta.• Research Support – AstraZeneca, Bayer, GlaxoSmithKline, Spectrum.• Royalties and Licensing fees – Spectrum.NY, SB, PM are employees and shareholders of GlaxoSmithKline.JRC is an employee of MedImmune.All other authors have no conflicts of interest to disclose.